Marshall Wace LLP Purchases Shares of 19,583 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Marshall Wace LLP acquired a new position in shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 19,583 shares of the biotechnology company’s stock, valued at approximately $422,000.

Several other hedge funds also recently modified their holdings of RCKT. Nisa Investment Advisors LLC grew its holdings in Rocket Pharmaceuticals by 31.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,160 shares of the biotechnology company’s stock worth $68,000 after buying an additional 764 shares in the last quarter. Old Well Partners LLC bought a new stake in shares of Rocket Pharmaceuticals in the 4th quarter worth $200,000. Virtu Financial LLC purchased a new stake in shares of Rocket Pharmaceuticals in the fourth quarter valued at about $332,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Rocket Pharmaceuticals by 30.5% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,092 shares of the biotechnology company’s stock valued at $368,000 after purchasing an additional 3,995 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Rocket Pharmaceuticals by 66.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 17,365 shares of the biotechnology company’s stock valued at $468,000 after purchasing an additional 6,941 shares in the last quarter. Institutional investors own 98.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on RCKT. Chardan Capital reissued a “buy” rating and issued a $62.00 price objective on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. JPMorgan Chase & Co. boosted their price target on shares of Rocket Pharmaceuticals from $50.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and set a $52.00 price objective on shares of Rocket Pharmaceuticals in a report on Tuesday, September 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $38.00 target price on shares of Rocket Pharmaceuticals in a research note on Monday, September 30th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $52.00.

Rocket Pharmaceuticals Stock Down 0.5 %

NASDAQ RCKT opened at $16.55 on Friday. Rocket Pharmaceuticals, Inc. has a 12 month low of $15.98 and a 12 month high of $32.53. The company has a current ratio of 7.79, a quick ratio of 7.79 and a debt-to-equity ratio of 0.05. The stock has a market cap of $1.50 billion, a PE ratio of -5.77 and a beta of 1.09. The stock’s 50 day moving average is $18.78 and its 200 day moving average is $21.58.

Rocket Pharmaceuticals (NASDAQ:RCKT) last posted its earnings results on Monday, August 5th. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.02). During the same quarter in the previous year, the firm earned ($0.82) EPS. Research analysts predict that Rocket Pharmaceuticals, Inc. will post -2.97 EPS for the current fiscal year.

Rocket Pharmaceuticals Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.